Pasello, Giulia <br/><br/>
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for   [electronic resource] 

 -  The oncologist  06 2019 
 - e318-e326 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2018-0712  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Afatinib--economics<br/>Aged<br/>Aged, 80 and over<br/>Carcinoma, Non-Small-Cell Lung--diagnosis<br/>Cost-Benefit Analysis<br/>Critical Pathways--standards<br/>DNA Mutational Analysis--standards<br/>Disease Progression<br/>Disease-Free Survival<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--economics<br/>Female<br/>Follow-Up Studies<br/>Gefitinib--economics<br/>Guideline Adherence--standards<br/>Humans<br/>Lung Neoplasms--diagnosis<br/>Male<br/>Middle Aged<br/>Mutation<br/>Practice Guidelines as Topic<br/>Progression-Free Survival<br/>Prospective Studies<br/>Protein Kinase Inhibitors--economics<br/>Time Factors<br/>Treatment Failure<br/>Assessment of Medication Adherence